Yuanyuan Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuanyuan Xie has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Chen Wang
Xiamen Xianyue Hospital, Xianyue Hospital Affiliated to Xiamen Medical College, Fujian Psychiatric Center, Fujian Clinical Research Center for Mental Disorders, Xiamen, Fujian Province, China
2 shared publications Guowei Tan
Department of Neurosurgery, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, Fujian, China
2 shared publicationsJianyao Mao
Department of Neurosurgery, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, Fujian, China
2 shared publications- Jinli Sun
Department of Reproduction, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, Fujian, China.
2 shared publications Liwei Zhou
Department of Neurosurgery, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, Fujian, China
2 shared publicationsSifang Chen
Department of Neurosurgery, The First Affiliated Hospital of Xiamen University, Xiamen, 361003, Fujian, China
2 shared publications
Latest Publications
- RetractionOpen Access
- 15 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 25508
Retraction Note: Reducing PKCδ inhibits tumor growth through growth hormone by inhibiting PKA/CREB/ERK signaling pathway in pituitary adenoma
- 15 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 25508
RetractionOpen AccessRetraction Note: Reducing PKCδ inhibits tumor growth through growth hormone by inhibiting PKA/CREB/ERK signaling pathway in pituitary adenoma
- RetractedOpen Access
- 3 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
RETRACTED ARTICLE: Reducing PKCδ inhibits tumor growth through growth hormone by inhibiting PKA/CREB/ERK signaling pathway in pituitary adenoma
Patients with growth hormone-secreting pituitary adenoma (GHPA) often fail to exhibit the molecular signatures typically associated with tumorigenesis. This study investigates the role of protein kinase C delta (PKCδ) in modulating cell apoptosis, migration, invasion, and tumor growth in pituitary adenoma. We assessed the activation of the PKA/CREB/ERK signaling pathway and cell apoptosis through RT-qPCR and western blot analysis. Wound-healing and transwell assays were employed to evaluate cell migration and invasion. Combined treatment with rottlerin and phorbol 12-myristate 13-acetate (PMA) reversed the inhibition of the PKA/CREB/ERK signaling pathway, downregulated cell apoptosis, and reduced growth hormone secretion in GH3 cells. A decrease in the level of PKCδ also inhibited the PKA/CREB/ERK signaling pathway, reduced cell apoptosis, and suppressed the secretion of growth hormone. Notably, growth hormone reversed the decline in cell migration and invasion following PKCδ siRNA treatment. Moreover, in nude mice with tumor models, growth hormone reversed the reduction in tumor volume induced by PKCδ siRNA. In conclusion, this study demonstrates that reducing PKCδ inhibits tumor growth by suppressing growth hormone via inhibition of the PKA/CREB/ERK signaling pathway.
- 3 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-13
RetractedOpen AccessRETRACTED ARTICLE: Reducing PKCδ inhibits tumor growth through growth hormone by inhibiting PKA/CREB/ERK signaling pathway in pituitary adenoma
Patients with growth hormone-secreting pituitary adenoma (GHPA) often fail to exhibit the molecular signatures typically associated with tumorigenesis. This study investigates the role of protein kinase C delta (PKCδ) in modulating cell apoptosis, migration, invasion, and tumor growth in pituitary adenoma. We assessed the activation of the PKA/CREB/ERK signaling pathway and cell apoptosis through RT-qPCR and western blot analysis. Wound-healing and transwell assays were employed to evaluate cell migration and invasion. Combined treatment with rottlerin and phorbol 12-myristate 13-acetate (PMA) reversed the inhibition of the PKA/CREB/ERK signaling pathway, downregulated cell apoptosis, and reduced growth hormone secretion in GH3 cells. A decrease in the level of PKCδ also inhibited the PKA/CREB/ERK signaling pathway, reduced cell apoptosis, and suppressed the secretion of growth hormone. Notably, growth hormone reversed the decline in cell migration and invasion following PKCδ siRNA treatment. Moreover, in nude mice with tumor models, growth hormone reversed the reduction in tumor volume induced by PKCδ siRNA. In conclusion, this study demonstrates that reducing PKCδ inhibits tumor growth by suppressing growth hormone via inhibition of the PKA/CREB/ERK signaling pathway.
- Open Access
- 27 April 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (5) , 112437
Apatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy
- 27 April 2023
- Published by Elsevier in Cell Reports
- Vol. 42 (5) , 112437
Open AccessApatinib remodels the immunosuppressive tumor ecosystem of gastric cancer enhancing anti-PD-1 immunotherapy